OncoCyte Corporation (OCX)

US — Healthcare Sector
Peers: BNR  STIM  DRIO  GTH  SERA  OLK  FONR  CSTL  XGN  PSNL  IDXG  ISPC  TRIB  INBS  BDSX  PRPO  PRPH  SHC 

Automate Your Wheel Strategy on OCX

With Tiblio's Option Bot, you can configure your own wheel strategy including OCX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol OCX
  • Rev/Share 0.1496
  • Book/Share 0.3977
  • PB 8.0215
  • Debt/Equity 0.3404
  • CurrentRatio 3.745
  • ROIC -1.1247

 

  • MktCap 91231767.0
  • FreeCF/Share -0.8925
  • PFCF -3.9785
  • PE -1.4082
  • Debt/Assets 0.0576
  • DivYield 0
  • ROE -7.6691

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation OCX Lake Street -- Buy -- $5 March 28, 2025

News

Best Momentum Stocks to Buy for May 6th
BYRN, MAIA, OCX
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive

MAIA, BYRN and OCX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 6, 2025.

Read More
image for news Best Momentum Stocks to Buy for May 6th
New Strong Buy Stocks for May 6th
BBVA, BYRN, HMY, MAIA, OCX
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive

MAIA, BYRN, OCX, BBVA and HMY have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2025.

Read More
image for news New Strong Buy Stocks for May 6th
Oncocyte Provides Positive Update on Clinical Trial Progress
OCX
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market.

Read More
image for news Oncocyte Provides Positive Update on Clinical Trial Progress
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity
OCX
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral

Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in Berlin Supports market expansion for testing of high-risk patient population New findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced the publication of new and positive data regarding its proprietary blood-based transplant rejection assay.

Read More
image for news Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
OCX
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive

OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?

About OncoCyte Corporation (OCX)

  • IPO Date 2015-12-30
  • Website https://oncocyte.com
  • Industry Biotechnology
  • CEO Mr. Joshua Riggs
  • Employees 46

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.